A Comprehensive Review of Ruxolitinib: Synthetic Strategies, Enantiomeric Precision, and Clinical Utility

Abstract

Ruxolitinib is a first-in-class selective JAK1/2 inhibitor that has transformed the management of myeloproliferative neoplasms (MPNs), specifically myelofibrosis and polycythemia vera. This paper reviews the therapeutic landscape and the significant synthetic evolution of the molecule. We analyze the transition from early medicinal chemistry routes, which relied on low-yield classical diastereomeric resolutions, to sophisticated industrial processes employing asymmetric catalysis. Key advancements, including organocatalysis, Rhodium-mediated addition, and catalytic hydrogenation, are evaluated for their impact on atom economy and enantiomeric precision. Furthermore, we discuss the strategic use of SEM and POM protecting groups and late-stage resolution with dibenzoyl-L-tartaric acid in achieving the high pharmaceutical purity required for clinical safety. Finally, an in silico ADMET and acute toxicity profiling is presented, validating the drug's favorable oral bioavailability, optimal central nervous system penetration limits, and predictable pharmacokinetic behavior. This overview highlights the critical synergy between clinical innovation, process chemistry, and computational profiling in modern drug development.